Shots:

• The P-IIb POC Study 201 involves assessing lecanemab in patients with early AD
• Results: @18mos- prespecified analysis showed a consistent reduction of clinical decline across several clinical and biomarker EPs at highest doses and reduction in brain Aβ & clinical decline. The results are published in a peer-reviewed journal
• In March- the companies have completed the enrolment in P-III OLE- Clarity AD trial that evaluate the safety & efficacy of lecanemab vs PBO in 1-795 symptomatic patients with early AD- following the outcome of P-IIb study. Additionally- the P-III AHEAD 3-45 study is currently evaluating lecanemab in individuals with preclinical AD

  Ref: PRNewswire | Image: Biogen